Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Virbac    VIRP   FR0000031577

VIRBAC

(VIRP)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Virbac : availability of the quarterly financial information as of March 31, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 03:10am EDT

Virbac: Availability of the quarterly financial informationas of March 31, 2019

Public release – May 15, 2019


The quarterly financial information as of March 31, 2019 is available:

• on our website: corporate.virbac.com under the section Investors – Financial reports – 2018;
• or on request, under legal and regulatory conditions.


In accordance with the terms implemented by the French financial markets authority (AMF), this document presents:

• significant operations and events of the period;
• a description of the group financial standing;
• the breakdown of revenue by business segment.


Virbac: NYSE Euronext - compartment B - ISIN code: FR0000031577/SYMBOL: VIRP
Corporate finance: +33 4 92 08 71 32 - finances@virbac.com - corporate.virbac.com


Attachment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VIRBAC
05/16VIRBAC : availability of the quarterly financial information as of March 31, 201..
GL
04/11VIRBAC : 2019 first quarter revenue rose by +10.9% at comparable exchange rates
GL
04/08VIRBAC SA : quaterly sales release
03/18VIRBAC : 2018 operating profit from ordinary activities grew by 13.4%
GL
03/13VIRBAC SA : annual earnings release
01/17VIRBAC : 2018 annual revenue grew by +4.5% at constant exchange rates
AQ
01/14VIRBAC SA : annual sales release
2018VIRBAC : Availability of the quarterly financial information as of September 30,..
AQ
2018VIRBAC : 2018 third quarter consolidated sales
PU
2018VIRBAC : revenue grew by +5.5% at constant exchange rates at the end of Septembe..
AQ
More news
Financials (€)
Sales 2019 924 M
EBIT 2019 95,6 M
Net income 2019 47,6 M
Debt 2019 398 M
Yield 2019 0,83%
P/E ratio 2019 29,17
P/E ratio 2020 23,95
EV / Sales 2019 1,94x
EV / Sales 2020 1,81x
Capitalization 1 392 M
Chart VIRBAC
Duration : Period :
Virbac Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIRBAC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 170 €
Spread / Average Target 3,5%
EPS Revisions
Managers
NameTitle
Christian Karst General Manager & EVP-Corporate Development
Marie-Hélène Dick-Madelpuech Chairman-Supervisory Board
Sébastien Huron Chairman
Habib Ramdani Chief Financial Officer
Jean-Pierre Dick Director-Executive Board
Sector and Competitors
1st jan.Capitalization (M$)
VIRBAC44.64%1 552
ZOETIS20.34%49 273
ELANCO ANIMAL HEALTH INC2.41%11 973
DECHRA PHARMACEUTICALS32.17%3 549
JINYU BIO-TECHNOLOGY CO LTD49.34%2 469
PHIBRO ANIMAL HEALTH CORP-8.18%1 185